| Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer M Michaut, SF Chin, I Majewski, TM Severson, T Bismeijer, L De Koning, ... Scientific reports 6 (1), 1-13, 2016 | 191 | 2016 |
| BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential TM Severson, J Peeters, I Majewski, M Michaut, A Bosma, PC Schouten, ... Molecular oncology 9 (8), 1528-1538, 2015 | 82 | 2015 |
| The BRCA1 ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting TM Severson, DM Wolf, C Yau, J Peeters, D Wehkam, PC Schouten, ... Breast Cancer Research 19 (1), 1-9, 2017 | 77 | 2017 |
| Radiogenomic analysis of breast cancer by linking MRI phenotypes with tumor gene expression T Bismeijer, BHM van der Velden, S Canisius, EH Lips, CE Loo, ... Radiology 296 (2), 277-287, 2020 | 46 | 2020 |
| A multilevel pan-cancer map links gene mutations to cancer hallmarks TA Knijnenburg, T Bismeijer, LFA Wessels, I Shmulevich Chinese journal of cancer 34, 1-11, 2015 | 29 | 2015 |
| Complementary value of contralateral parenchymal enhancement on DCE-MRI to prognostic models and molecular assays in high-risk ER+/HER2− breast cancer BHM van der Velden, SG Elias, T Bismeijer, CE Loo, MA Viergever, ... Clinical Cancer Research 23 (21), 6505-6515, 2017 | 22 | 2017 |
| Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo Y Kim, T Bismeijer, W Zwart, LFA Wessels, DJ Vis Nature communications 10 (1), 5034, 2019 | 20 | 2019 |
| Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis T Bismeijer, S Canisius, LFA Wessels PLoS computational biology 14 (10), e1006520, 2018 | 15 | 2018 |
| Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ MMM Almekinders, M Schaapveld, B Thijssen, LL Visser, T Bismeijer, ... NPJ Breast Cancer 7 (1), 31, 2021 | 11 | 2021 |
| Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related? BHM van der Velden, T Bismeijer, S Canisius, CE Loo, EH Lips, ... European Journal of Radiology 121, 108705, 2019 | 9 | 2019 |
| Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk MM Almekinders, T Bismeijer, T Kumar, F Yang, B Thijssen, ... British journal of cancer 127 (7), 1201-1213, 2022 | 6 | 2022 |
| Perfusion in the contralateral breast on preoperative MRI may complement ER-pathway activity from the index tumor to stratify outcome of endocrine therapy for early-stage … B Van der Velden, T Bismeijer, S Canisius, C Loo, E Lips, J Wesseling, ... European Journal of Cancer 92, S49-S50, 2018 | 2 | 2018 |
| Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients MAA Ragusi, T Bismeijer, BHM van der Velden, CE Loo, S Canisius, ... The Breast 60, 230-237, 2021 | 1 | 2021 |
| Abstract PR002: Genomic predictor can discriminate between high-and low-risk DCIS MR Escorza, M Sheinman, T Bismeijer, AA Ahmed, V Shah, JR Marks, ... Cancer Prevention Research 15 (12_Supplement_1), PR002-PR002, 2022 | | 2022 |
| Copy number analysis of pure DCIS and association with recurrence AA Ahmed, M Roman-Escorza, T Bismeijer, M Sheinman, V Shah, ... Cancer Research 82 (12_Supplement), 5108-5108, 2022 | | 2022 |
| Abstract P1-22-05: Identifying predictors of invasive recurrence based on molecular profiles of DCIS lesions T Bismeijer, AA Ahmed, M Sheinman, M Roman-Escorza, V Shah, ... Cancer Research 82 (4_Supplement), P1-22-05-P1-22-05, 2022 | | 2022 |
| Ductal carcinoma in situ of the breast: Cancer precursor or not L Visser, M Hoogstraat, T Bismeijer, L Elshof, K van de Vijver, E Groen, ... Cancer Research 79 (13 Supplement), 751-751, 2019 | | 2019 |
| Progression of ductal carcinoma in situ (DCIS), is it in the immune microenvironment MM Almekinders, L Visser, B Thijssen, R Linden, C Rooijen, P Kristel, ... Cancer Research 79 (13_Supplement), 2806-2806, 2019 | | 2019 |
| Characterizing heterogeneity between cancer patients by integrating molecular data, imaging data and pre-existing knowledge T Bismeijer Utrecht University, 2019 | | 2019 |
| Methods and means for subtyping invasive lobular breast cancer T Bismeijer, M Michaut, R Bernards, LFA Wessels US Patent App. 15/558,465, 2018 | | 2018 |
